All News

HAYA Therapeutics Secures $65 Million Series A to Advance RNA-Guided Therapies for Chronic and Age-Related Diseases

Read more

Published on

Socials

01

Follow Us

Read more

02

Other Articles

News

HAYA's CEO Sees a Future Where His Therapy Could Treat Cancer and Alzheimer’s

@haya
News

Samir Ounzain, HAYA's CEO, Recognized as One of the 100 Personalities Shaping French-Speaking Switzerland

@haya
News

Interview with Eric Adam, COO of HAYA Therapeutics

@haya
Back to articles